Latest News on COLL

Financial News Based On Company


Advertisement
Advertisement

Janus Henderson Group Discloses 0.2% Stake in Collegium Pharmaceutical in Amended SEC Filing

https://kalkinemedia.com/us/news/announcements/janus-henderson-group-discloses-02-stake-in-collegium-pharmaceutical-in-amended-sec-filing
Janus Henderson Group Ltd. filed an amended Schedule 13G with the SEC, revealing a beneficial ownership of 64,540 shares of Collegium Pharmaceutical, Inc. common stock, representing 0.2% of the outstanding shares as of September 30, 2026. The filing details that Janus Henderson, as a parent holding company, exercises investment and voting discretion through its Asset Managers for various client accounts, but disclaims rights to dividends or sale proceeds from these securities. No single portfolio managed by Janus Henderson holds more than 5% of Collegium Pharmaceutical's common stock.

Janus Henderson reports shared voting power over 64,540 Collegium (COLL) shares, a 0.2% stake.

https://www.stocktitan.net/sec-filings/COLL/schedule-13g-a-collegium-pharmaceutical-inc-amended-passive-investmen-87dc9139b849.html
Janus Henderson Group Ltd. has filed an amended Schedule 13G/A, reporting shared voting and dispositive power over 64,540 common shares of Collegium Pharmaceutical, Inc. (COLL), representing a 0.2% stake. The Asset Managers within Janus Henderson exercise investment and voting discretion for client-managed portfolios, which hold the rights to dividends and sale proceeds. No single managed portfolio owns more than 5% of COLL's common stock.

A holder reports 5% or less of Collegium (COLL), with sole voting power over its shares.

https://www.stocktitan.net/sec-filings/COLL/schedule-13g-a-collegium-pharmaceutical-inc-amended-passive-investmen-12a2863b9bb8.html
Fuller & Thaler Asset Management, Inc. has filed an amended passive investment disclosure (SCHEDULE 13G/A) for Collegium Pharmaceutical, Inc. (COLL). As of September 30, 2026, the firm reported beneficial ownership of 598,540.14 common shares, representing 1.84% of the class. Fuller & Thaler holds sole voting and sole dispositive power over these shares, indicating ownership of 5% or less.

Barclays maintains Collegium Pharmaceutical at Overweight, lowers price target to $41 from $48

https://www.tradingview.com/news/tradingview:9c786a9a10cf2:0-barclays-maintains-collegium-pharmaceutical-at-overweight-lowers-price-target-to-41-from-48/
Barclays has reiterated its "Overweight" rating for Collegium Pharmaceutical (COLL) but reduced its price target from $48 to $41, a 14.6% decrease. The new price target suggests a potential upside of 61.9% from the stock's closing price of $25.32 on November 13.

Client-held shares underpin Invesco’s amended ownership report for Collegium (COLL).

https://www.stocktitan.net/sec-filings/COLL/schedule-13g-a-collegium-pharmaceutical-inc-amended-passive-investmen-646c569d5e09.html
Invesco Ltd. has filed an amended Schedule 13G/A report indicating a beneficial ownership of 1,261,037 shares, or 3.9%, of Collegium Pharmaceutical, Inc. (COLL) common stock as of September 30, 2026. These shares are held by Invesco's clients, who retain the rights to dividends and sale proceeds, with no single client holding more than 5% economic ownership. The filing details Invesco's sole voting power over 1,260,828 shares and sole dispositive power over all 1,261,037 shares.
Advertisement

State Street reports a passive stake in Collegium (COLL) with no sole voting power.

https://www.stocktitan.net/sec-filings/COLL/schedule-13g-collegium-pharmaceutical-inc-passive-investment-disclosu-5b9e3de216d7.html
State Street Corporation has reported a 5.4% passive stake in Collegium Pharmaceutical, Inc. (COLL), as disclosed in a SCHEDULE 13G SEC filing. The firm holds shared voting power over 1,689,578 shares and shared dispositive power over 1,772,243 shares, indicating no sole voting or dispositive control. This filing highlights State Street's beneficial ownership without intent to influence the control of the issuer.

Collegium Pharmaceutical, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:COLL) 2026-11-07

https://seekingalpha.com/article/4964799-collegium-pharmaceutical-inc-2026-q3-results-earnings-call-presentation
Collegium Pharmaceutical, Inc. (COLL) released its Q3 2026 earnings call presentation, reporting an EPS of $1.96, which beat estimates by $0.10. The company also announced revenue of $216.34 million, exceeding expectations by $304.71K and representing a 3.33% year-over-year increase. This presentation was published in conjunction with their earnings call.

Collegium Pharmaceutical Q3 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:6c622eb18094b:0-collegium-pharmaceutical-q3-earnings-call-highlights/
Collegium Pharmaceutical (COLL) reported record third-quarter 2026 revenue of $216.3 million, driven by a 24% increase in JORNAY PM sales and $26.5 million from AZSTARYS, which now make up over 36% of total revenue. Despite a decline in net income and adjusted EBITDA, the company reaffirmed its full-year 2026 outlook. The company's ADHD portfolio showed strong prescription growth, while its pain portfolio faced pressure from generic competition and payer issues.

Collegium Pharmaceutical Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62920002/collegium-pharmaceutical-q3-2026-earnings-call-transcript
Collegium Pharmaceutical reported a record quarterly net revenue of $216.3 million in Q3 2026, marking a 3% year-over-year increase, primarily fueled by the strong performance of its ADHD portfolio, including Jornay PM and Azstarys. The ADHD segment now constitutes over 36% of total revenue, with Jornay PM prescriptions growing 16% year-over-year and Azstarys generating $26.5 million in its first full quarter under Collegium's ownership. The company reaffirmed its 2026 financial guidance, emphasizing continued growth in the ADHD business, sustained cash flow from its pain portfolio, and strategic capital allocation including a $50 million accelerated share repurchase program.

Collegium Pharma (COLL) Tops Q3 EPS by 10c; Offers Guidance

https://www.streetinsider.com/Earnings/Collegium+Pharma+%28COLL%29+Tops+Q3+EPS+by+10c%3B+Offers+Guidance/27295511.html
Collegium Pharma (NASDAQ: COLL) reported strong Q3 earnings, surpassing analyst estimates with an EPS of $1.96, which was $0.10 higher than expected. The company's revenue for the quarter was $216.3 million, aligning closely with consensus estimates. Additionally, Collegium Pharma provided FY2026 revenue guidance of $825-855 million, with a consensus of $833.1 million.
Advertisement

Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance

https://www.globenewswire.com/news-release/2026/11/05/3396299/34897/en/collegium-reports-third-quarter-2026-financial-results-reaffirms-2026-guidance.html
Collegium Pharmaceutical, Inc. announced its third quarter 2026 financial results, highlighting record quarterly net revenues of $216.3 million, a 3% increase year-over-year. The company saw strong demand in its ADHD portfolio, with JORNAY PM® revenue up 24% and AZSTARYS® generating $26.5 million in its first full quarter under Collegium ownership. Collegium reaffirmed its full-year 2026 financial guidance and is executing a $50 million accelerated share repurchase program.

FinancialContent - Collegium Pharmaceutical (NASDAQ:COLL) posts in line Q3 2026 sales and full year revenue guidance above estimates, stock soars

https://markets.financialcontent.com/stocks/article/stockstory-2026-11-5-collegium-pharmaceutical-nasdaqcoll-posts-in-line-q3-2026-sales-and-full-year-revenue-guidance-above-estimates-stock-soars
Collegium Pharmaceutical (NASDAQ: COLL) reported Q3 2026 revenue of $216.3 million, meeting Wall Street expectations, and full-year revenue guidance of $840 million, which is slightly above consensus estimates. The company's non-GAAP profit per share exceeded analyst expectations, leading to a 6.7% surge in stock price. Strong demand for its ADHD portfolio, particularly JORNAY PM and AZSTARYS, contributed to these positive results.

Collegium Pharmaceutical Inc (354.MU) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/354.MU/seasonality/
The article provides a seasonal returns chart for Collegium Pharmaceutical Inc (354.MU), showing the average monthly price return from 2022 to 2026. It also includes current stock information, financial data, and details about the upcoming Q3 2026 earnings call. The stock is listed on the Munich exchange.

Collegium Pharmaceutical, Inc. (COLL) Seasonal returns chart

https://uk.finance.yahoo.com/quote/COLL/seasonality/
This article presents a seasonal returns chart for Collegium Pharmaceutical, Inc. (COLL), showing the average monthly price return from 2016 to 2026. It also notes the upcoming Q3 2026 earnings call for COLL scheduled for November 5, 2026. The stock's current price and after-hours performance are also displayed.

Vanguard reports voting power over 245,798 Collegium (COLL) shares, alongside a larger stake.

https://www.stocktitan.net/sec-filings/COLL/schedule-13g-a-collegium-pharmaceutical-inc-amended-passive-investmen-302a5c8f2997.html
Vanguard Capital Management has reported a 4.97% beneficial ownership stake in Collegium Pharmaceutical, Inc., totaling 1,621,026 shares. The investment firm holds sole voting power over 245,798 shares and sole dispositive power over all 1,621,026 shares. This disclosure, filed via an amended Schedule 13G/A, indicates that Vanguard's investment companies and managed accounts maintain rights to dividends and proceeds from these securities.
Advertisement

Collegium Pharmaceutical, Inc. (COLL) Stock forecasts

https://sg.finance.yahoo.com/research/reports/ARGUS_5963_QuantitativeReport_1793145600000
This article provides a brief overview of Collegium Pharmaceutical Inc. (COLL), noting it as a specialty pharmaceutical company. It highlights an Argus report dated October 28, 2026, which offers an unspecified rating and earnings estimate for COLL, with a current price of $23.80 and a price target available in the full report. The content also lists related reports for other companies, indicating a focus on analyst insights for pharmaceutical stocks.

An investor reports 5% or less of Collegium Pharmaceutical (COLL) and shares voting power.

https://www.stocktitan.net/sec-filings/COLL/schedule-13g-a-collegium-pharmaceutical-inc-amended-passive-investmen-fd20e64e3f7a.html
Principal Global Investors reported a beneficial ownership of 1,514,310 shares, or 4.7%, of Collegium Pharmaceutical, Inc. (COLL) common stock as of September 30, 2026. This position falls within the stated ownership category of 5% or less. The firm also reported shared voting and shared dispositive power over these shares, with no sole voting or dispositive power.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

https://pluang.com/en/news-feed/collegium-pharmaceutical-boston-legacy-fc-perluas-kemitraan-dukungan-komunitas
Collegium Pharmaceutical and Boston Legacy FC have expanded their partnership to enhance support for neurodivergent youth, particularly those with ADHD, in Massachusetts sports. The multi-year initiative includes youth coach training, an annual "Sports for All Summit," and sensory inclusion programs, aiming to create more inclusive sports environments. This aligns with Collegium's move to Boston in 2027 and its broader goal of regional and national expansion.

Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts

https://www.globenewswire.com/news-release/2026/10/29/3391167/0/en/collegium-pharmaceutical-and-boston-legacy-fc-expand-their-partnership-beyond-matchday-to-communities-across-massachusetts.html
Collegium Pharmaceutical and Boston Legacy FC have announced an expanded, multi-year partnership to support neurodivergent children and families, including those living with ADHD, across Massachusetts. The initiative includes a coaching certification program, an annual "Sports for All" summit, and continued sensory inclusion efforts. This partnership aims to make youth sports more accessible and inclusive, reflecting Collegium's commitment to community engagement ahead of its headquarters relocation to Boston in early 2027.

Weekly Recap: NASDAQ:COLL Q3 2026 results and Grünenthal $17M settlement

https://www.tradingview.com/news/tradingview:ba1ae8d10befe:0-weekly-recap-nasdaq-coll-q3-2026-results-and-gr-nenthal-17m-settlement/
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is set to report its Q3 2026 results on November 5, 2026. This comes after the company recently settled with Grünenthal for $17 million and announced seven ADHD presentations, including pediatric AZSTARYS Phase 4 data and adult JORNAY PM real-world analyses.
Advertisement

Collegium Pharmaceutical, Inc. Estimates – TRADEGATE:354

https://www.tradingview.com/symbols/TRADEGATE-354/financials-estimates/
The article provides an overview of Collegium Pharmaceutical, Inc. (TRADEGATE:354) financials and analyst estimates on TradingView. It allows users to explore reported financial data and compare actual results with average, high, and low estimates across various financial statements. The platform offers tools for visualizing trends over time for the company.

Collegium Pharmaceutical, Inc. Estimates – NASDAQ:COLL

https://www.tradingview.com/symbols/NASDAQ-COLL/financials-estimates/
This article provides access to financial actuals and analyst estimates for Collegium Pharmaceutical, Inc. (NASDAQ: COLL). Users can explore reported financial data and compare actual results with average, high, and low estimates across various financial statements and valuation metrics. The platform also visualizes trends over time for the company's financial performance.

Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026

https://www.globenewswire.com/news-release/2026/10/22/3386247/34897/en/collegium-to-report-third-quarter-2026-financial-results-on-november-5-2026.html
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced it will report its third quarter 2026 financial results before the market opens on Thursday, November 5, 2026. Following the release, the company will host a live conference call and webcast at 8:00 a.m. ET to discuss the results. The webcast will be available for replay on the Investors section of Collegium's website.

Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026

https://www.globenewswire.com/news-release/2026/10/22/3386247/0/en/collegium-to-report-third-quarter-2026-financial-results-on-november-5-2026.html
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced it will report its third quarter 2026 financial results before the market opens on Thursday, November 5, 2026. Following the release, the company will host a live conference call and webcast at 8:00 a.m. ET to discuss the results. The webcast will be available for replay on the company's website.

Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses

https://www.globenewswire.com/news-release/2026/10/21/3385443/34897/en/collegium-to-present-pediatric-and-real-world-research-across-adhd-portfolio-at-aacap-and-nei-fall-congresses.html
Collegium Pharmaceutical, Inc. announced that seven abstracts from its ADHD portfolio have been accepted for presentation at two upcoming scientific congresses: the AACAP 2026 Annual Meeting and the NEI Fall Congress. The presentations will cover pediatric Phase 4 studies of AZSTARYS® and real-world research on JORNAY PM® in adults, including its impact on caregivers. This research aims to deepen the understanding of daily needs and advance ADHD management across different age groups and real-life settings.
Advertisement

Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses

https://www.globenewswire.com/fr/news-release/2026/10/21/3385443/0/en/collegium-to-present-pediatric-and-real-world-research-across-adhd-portfolio-at-aacap-and-nei-fall-congresses.html
Collegium Pharmaceutical, Inc. announced that seven abstracts from its ADHD portfolio have been accepted for presentation at two scientific congresses this fall: the American Academy of Child and Adolescent Psychiatry (AACAP) 2026 Annual Meeting and the Neuroscience Education Institute (NEI) Fall Congress. The presentations will cover pediatric clinical studies of AZSTARYS® and real-world research of JORNAY PM® in adults and their caregivers, aiming to enhance the understanding of ADHD across different age groups and daily settings. This research underscores Collegium's commitment to advancing ADHD management and addressing the daily needs of individuals and families affected by the condition.

Collegium Pharmaceutical, Inc. (COLL) Stock forecasts

https://sg.finance.yahoo.com/research/reports/ARGUS_5963_QuantitativeReport_1791936000000/
Argus has lowered its target price for Collegium Pharmaceutical Inc. (COLL) to $20.00, while the current stock price stands at $22.91. Collegium Pharmaceutical Inc. is identified as a specialty pharmaceutical company. The report, published on October 14, 2026, is part of a quantitative analysis within the healthcare sector.

Zacks upgrades Collegium Pharmaceutical stock to strong buy

https://www.ad-hoc-news.de/boerse/news/nebenwerte/zacks-upgrades-collegium-pharmaceutical-stock-to-strong-buy/70378417
Zacks Research has upgraded Collegium Pharmaceutical (COLL) stock from "strong sell" to "strong buy" following its second-quarter 2026 revenue of USD 199.88 million, a 6.00% increase year-over-year. Despite a GAAP net loss, the company saw significant growth in Jornay PM revenue while its Nucynta franchise declined. Investors are now looking to the upcoming Q3 earnings release on November 5, 2026, for further insight into the company's performance.

Zacks upgrades Collegium Pharmaceutical stock to strong buy

https://www.ad-hoc-news.de/boerse/news/nebenwerte/zacks-upgrades-collegium-pharmaceutical-stock-to-strong-buy/70349672
Zacks Research has upgraded Collegium Pharmaceutical (COLL) stock from strong sell to strong buy as of October 17, 2026. The stock was trading at EUR 19.50, up 0.52 percent, with a trailing P/E ratio of 18.70 and a market capitalization of USD 755.0 million. Collegium Pharmaceutical, a specialty pharmaceuticals company, is scheduled to report its next earnings on November 5, 2026.

Living with ADHD? Three ways to find support and feel less alone

https://www.huntingdondailynews.com/online_features/health_and_wellness/living-with-adhd-three-ways-to-find-support-and-feel-less-alone/article_39d4b950-da11-5d29-ba86-62f813d09579.html
This article offers three ways for individuals with ADHD and their families to find support and feel less isolated. It emphasizes the importance of starting with trusted resources, building a strong support network, and preparing for meaningful conversations with healthcare providers. These steps aim to help individuals navigate their ADHD journey with more confidence and understanding.
Advertisement

Barclays Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Maintains Target Price $48

https://www.moomoo.com/news/post/1001289215/barclays-maintains-collegium-pharmaceutical-collus-with-buy-rating-maintains-target
Barclays has reiterated its Buy rating on Collegium Pharmaceutical (COLL.US), maintaining a target price of $48. This indicates the firm's continued confidence in the company's stock performance.

Collegium Pharmaceutical stock has a November 5 earnings date

https://www.ad-hoc-news.de/boerse/news/nebenwerte/collegium-pharmaceutical-stock-has-a-november-5-earnings-date/70332993
Collegium Pharmaceutical (COLL) is scheduled to report its third-quarter 2026 earnings on November 5, 2026, before the market opens. As of October 15, 2026, the stock was trading at EUR 20.70 on Lang & Schwarz and USD 23.30 on Nasdaq, with a P/E ratio of 18.79 and a market capitalization of USD 758.5 million. The company specializes in pain management and neuropsychiatry pharmaceuticals.

COLL5756983 Bond Profile: Coupon and Redemption

https://www.tradingview.com/symbols/FINRA-COLL5756983/profile/
This article provides a detailed profile of the COLL5756983 bond issued by Collegium Pharmaceutical, Inc. It outlines key facts such as the issuer, issue and maturity dates, face value, and interest payment details. The bond has a fixed rate of 2.88% paid semi-annually, with its redemption outstanding amount noted at $241.50 million USD.

Behavioral Patterns of COLL and Institutional Flows

https://news.stocktradersdaily.com/news_release/8/Behavioral_Patterns_of_COLL_and_Institutional_Flows_101126034402_1791704642.html
This article analyzes Collegium Pharmaceutical Inc. (NASDAQ: COLL), identifying a near-term neutral sentiment amidst mid and long-term weakness. It highlights an exceptional risk-reward setup targeting a 29.5% gain versus 0.3% risk and outlines three institutional trading strategies tailored for different risk profiles. The analysis includes AI-generated signals and multi-timeframe support/resistance levels.

An estimated 15.5 million U.S. adults have ADHD. Three guides help families navigate care and school.

https://www.stocktitan.net/news/COLL/collegium-launches-start-talking-adhd-with-practical-support-to-help-0vgqsof9otjx.html
Collegium Pharmaceutical (COLL) has launched "Start Talking ADHD," an online resource hub providing practical guides for individuals with ADHD and their families. These guides aim to facilitate better conversations with healthcare providers, schools, and support networks. The initiative underscores Collegium's commitment to supporting the ADHD community beyond medication, building on its expanded ADHD portfolio.
Advertisement

Collegium Pharmaceutical, Inc. (COLL) Stock forecasts

https://uk.finance.yahoo.com/research/reports/ARGUS_5963_QuantitativeReport_1791331200000
This article provides a stock forecast for Collegium Pharmaceutical, Inc. (COLL) from Argus, dated October 7, 2026. It identifies Collegium Pharmaceutical as a specialty pharmaceutical company and indicates a current price of $22.09, but the full report details are behind a paywall. The article also lists other related reports with lowered target prices for different companies.

Four investors report shared voting power over Collegium Pharma (COLL) shares.

https://www.stocktitan.net/sec-filings/COLL/schedule-13g-a-collegium-pharmaceutical-inc-amended-passive-investmen-f29074c7b639.html
Four investors, including Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, have reported shared voting and dispositive power over shares of Collegium Pharmaceutical, Inc. (COLL) in an amended Schedule 13G/A filing. Integrated Core Strategies (US) LLC reported beneficial ownership of 1,897,471 shares (5.8%), while Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each reported 2,400,985 shares (7.4%). The filing clarifies that the disclosures for Millennium-related entities are not an admission of beneficial ownership but relate to securities held by entities under their control.

Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life

https://www.globenewswire.com/news-release/2026/10/06/3375438/34897/en/collegium-launches-start-talking-adhd-with-practical-support-to-help-families-navigate-care-school-and-everyday-life.html
Collegium Pharmaceutical, Inc. has launched "Start Talking ADHD," an online resource hub to provide practical guides for individuals with ADHD and their families. These guides aim to facilitate better communication with healthcare providers and school administrators by helping users articulate their daily experiences with ADHD. The initiative is part of Collegium's broader commitment to supporting the ADHD community beyond clinical treatment, including expanding its medication portfolio and community involvement.

Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life

https://www.globenewswire.com/news-release/2026/10/06/3375438/0/en/collegium-launches-start-talking-adhd-with-practical-support-to-help-families-navigate-care-school-and-everyday-life.html
Collegium Pharmaceutical, Inc. has launched "Start Talking ADHD," an online resource hub providing practical guides for individuals with ADHD and their families. These guides aim to facilitate better communication with healthcare providers, school administrators, and support networks. The initiative underscores Collegium's commitment to supporting people beyond clinical settings and builds on its expanding ADHD portfolio.

Oppenheimer starts coverage of Collegium Pharmaceutical stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/oppenheimer-starts-coverage-of-collegium-pharmaceutical-stock/70238145
Oppenheimer has initiated coverage of Collegium Pharmaceutical (COLL) with an Outperform rating and a $50.00 price target, highlighting the company's strategic shift from pain medicines to central nervous system products, including recent acquisitions in ADHD treatments. Collegium Pharmaceutical reported a 6% year-over-year revenue increase in Q2 2026 to $199.9 million, with full-year guidance set at $825-855 million. The company's market capitalization stood at $709.3 million as of October 5, 2026.
Advertisement

Collegium Pharmaceutical stock reports ADHD growth in Q2

https://www.ad-hoc-news.de/boerse/news/corporate-news/collegium-pharmaceutical-stock-reports-adhd-growth-in-q2/70237265
Collegium Pharmaceutical reported a 6% year-over-year increase in Q2 2026 net product revenue, reaching USD 199.9 million, primarily driven by its ADHD portfolio. Jornay PM revenue surged by 41% to USD 46.1 million, and Azstarys contributed USD 12.9 million in its first partial quarter after acquisition. Despite a strong outlook for ADHD drugs, the pain portfolio's Nucynta revenue declined, leading to an adjusted EBITDA forecast that is essentially flat compared to 2025.

Collegium Pharmaceutical Reports Q2 2026 Results: Full Earnings Call Transcript

https://www.benzinga.com/news/26/10/62156443/collegium-pharmaceutical-reports-q2-2026-results-full-earnings-call-transcript
Collegium Pharmaceutical reported strong Q2 2026 results, driven by significant growth in its ADHD business, particularly with Jornay PM and the newly acquired Azstarys. While the pain portfolio saw mixed results due to lower net pricing for Nucynta generics, the company updated its 2026 guidance with increased expectations for Azstarys and maintained its long-term strategic focus on CNS and rare diseases. Collegium is relocating its headquarters to Boston in 2027 and remains committed to disciplined capital deployment, including potential future acquisitions.

Oppenheimer sets USD 50.00 target for Collegium Pharmaceutical stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/oppenheimer-sets-usd-50-00-target-for-collegium-pharmaceutical-stock/70215085
Oppenheimer has initiated coverage on Collegium Pharmaceutical (COLL) with an Outperform rating and a USD 50.00 price target. The company's second-quarter revenue reached USD 199.88 million, up 6.30 percent, with ADHD portfolio growth offsetting pressure on older pain products. Collegium Pharmaceutical was trading at EUR 19.65 at Lang & Schwarz, up 1.03 percent.

Form 144 COLLEGIUM PHARMACEUTICAL For: 1 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-144-collegium-pharmaceutical-for-1-october-93CH-2717527
This article from Investing.com announces a Form 144 filing for COLLEGIUM PHARMACEUTICAL on October 1st. Form 144 filings indicate an insider's intent to sell restricted stock, but the article provides no further details regarding the transaction itself. It appears to be an automated notification of the filing.

Form 144 COLLEGIUM PHARMACEUTICAL For: 1 October By Investing.com

https://uk.investing.com/news/stock-market-news/form-144-collegium-pharmaceutical-for-1-october-93CH-4891112
This article reports on the filing of Form 144 by COLLEGIUM PHARMACEUTICAL for October 1st. Form 144 is filed with the SEC when an insider intends to sell restricted or controlled securities. The article does not provide further details regarding the nature of the filing.
Advertisement

Form 144 COLLEGIUM PHARMACEUTICAL For: 1 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-collegium-pharmaceutical-for-1-october-93CH-4861604
This article announces the filing of Form 144 for COLLEGIUM PHARMACEUTICAL on October 1, 2026. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity. The brief post from Investing.com provides no further details beyond this announcement.

Precision Trading with Collegium Pharmaceutical Inc. (COLL) Risk Zones

https://news.stocktradersdaily.com/news_release/1/Precision_Trading_with_Collegium_Pharmaceutical_Inc._COLL_Risk_Zones_093026090201_1790816521.html
The article provides a detailed analysis of Collegium Pharmaceutical Inc. (COLL) using AI models to identify precision trading risk zones. It highlights near-term weak sentiment, a potential test of support, and an exceptional risk-reward setup targeting a 30.3% gain versus 0.3% risk. Three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—are presented with specific entry, target, and stop-loss zones based on multi-timeframe signal analysis.

Former officer Scott Dreyer proposes selling 27,419 Collegium Pharmaceutical (COLL) shares.

https://www.stocktitan.net/sec-filings/COLL/144-collegium-pharmaceutical-inc-sec-filing-48faec967457.html
Former Collegium Pharmaceutical (COLL) officer Scott Dreyer has proposed selling 27,419 common shares with an aggregate market value of $603,320.70. The proposed sale, dated September 30, 2026, is being conducted through Fidelity Brokerage Services LLC and is related to restricted stock vesting for compensation. The Form 144 filing indicates that the securities were acquired on September 23, 2026, through restricted stock vesting.

Collegium Pharmaceutical, Inc. (COLL) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_5963_QuantitativeReport_1790121600000
Argus has issued a research report on Collegium Pharmaceutical Inc. (COLL), raising its target price to $22.00. The report, published on September 23, 2026, indicates a current stock price of $22.53. Collegium Pharmaceutical Inc. is identified as a specialty pharmaceutical company.

Collegium Pharmaceutical stock falls 1.45 percent near yearly low

https://www.ad-hoc-news.de/boerse/news/nebenwerte/collegium-pharmaceutical-stock-falls-1-45-percent-near-yearly-low/70174466
Collegium Pharmaceutical stock fell 1.45% to USD 22.45 on September 23, 2026, placing it 3.7% above its 52-week low. Despite this, the company reported a 6.3% increase in Q2 2026 revenue, reaching USD 199.9 million, and adjusted EPS of USD 1.92, exceeding analyst estimates. Oppenheimer initiated coverage with an Outperform rating and a price target of USD 50.00, suggesting a significant upside.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement